Dr. Oaknin Discusses Findings of the GARNET Study in Endometrial Cancer

Ana Oaknin, MD
Published: Monday, May 20, 2019



Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses findings of the GARNET study in endometrial cancer.

The phase I/II GARNET trial is the largest study analyzing an anti–PD-1 monoclonal antibody in patients with advanced endometrial cancer. In the study, dostarlimab (TSR-042) demonstrated a clinically meaningful overall response rate (ORR) in all patients irrespective of microsatellite instability (MSI) status. ORR in the overall population was approximately 30%. In the microsatellite–stable population, ORR was 20.3%. In the MSI–high population, ORR was 48.8%, Oaknin says.

The most promising aspect of this study was the duration of response, she adds. Although median duration of response has not been reached, 89% of patients remained on treatment for more than 6 months and 49% of patients remained on treatment for more than 1 year. This is important, Oaknin concludes, because patients with advanced endometrial cancer remain a significant unmet need.
SELECTED
LANGUAGE


Ana Oaknin, MD, principal investigator, Vall d’Hebron Institute of Oncology, Gynecological Malignancies Group, head of Gynecologic Tumors Unit, Medical Oncology Department, Vall d’Hebron University Hospital, discusses findings of the GARNET study in endometrial cancer.

The phase I/II GARNET trial is the largest study analyzing an anti–PD-1 monoclonal antibody in patients with advanced endometrial cancer. In the study, dostarlimab (TSR-042) demonstrated a clinically meaningful overall response rate (ORR) in all patients irrespective of microsatellite instability (MSI) status. ORR in the overall population was approximately 30%. In the microsatellite–stable population, ORR was 20.3%. In the MSI–high population, ORR was 48.8%, Oaknin says.

The most promising aspect of this study was the duration of response, she adds. Although median duration of response has not been reached, 89% of patients remained on treatment for more than 6 months and 49% of patients remained on treatment for more than 1 year. This is important, Oaknin concludes, because patients with advanced endometrial cancer remain a significant unmet need.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x